BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn Investment Management Ltd. has increased its holdings in BioCryst Pharmaceuticals by 64.5%, owning 1,042,424 shares valued at approximately $7.8 million.
• The stock has recently performed well, reporting a 49.5% increase in revenue, with earnings of $0.15 EPS for the quarter, significantly surpassing analyst estimates.
• Analysts have set an average target price of $16.70 for BioCryst, with multiple ratings indicating a positive outlook on the stock, including "overweight" and "strong-buy" recommendations.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 64.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,042,424 shares of the biotechnology company's stock after acquiring an additional 408,560 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.50% of BioCryst Pharmaceuticals worth $7,818,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allianz Asset Management GmbH increased its stake in BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock worth $103,000 after acquiring an additional 1,200 shares during the last quarter. SG Americas Securities LLC increased its stake in BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock worth $326,000 after acquiring an additional 2,146 shares during the last quarter. Mariner LLC boosted its position in shares of BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after buying an additional 3,224 shares during the period. Quantinno Capital Management LP boosted its position in shares of BioCryst Pharmaceuticals by 38.2% during the fourth quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock valued at $112,000 after buying an additional 4,097 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $32,000. 85.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several recent analyst reports. Wedbush boosted their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.05 during mid-day trading on Friday, hitting $8.40. The company's stock had a trading volume of 1,615,633 shares, compared to its average volume of 3,842,827. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -46.69, a PEG ratio of 1.94 and a beta of 1.10. The business's fifty day moving average is $9.11 and its two-hundred day moving average is $8.77.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. During the same period in the previous year, the company earned ($0.06) earnings per share. The company's revenue was up 49.5% compared to the same quarter last year. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares in the company, valued at $556,145.52. This represents a 51.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.